ARC Pharmaceuticals, Inc.

Pharmaceutical firm granted U.S. patent related to surgical adhesion therapy

Published in Drug Law Weekly, May 3rd, 2005

ARC Pharmaceuticals, Inc., (ARC) announced that The University of British Columbia (UBC) has been granted a new U.S. patent entitled "Pharmaceutical Compositions and Methods Relating to Fucans," No. 6,812,220.

The patent protects key intellectual property exclusively licensed to ARC that may be used in the development of ARC's lead product candidates for the treatment of surgical adhesions.

"This issued patent strengthens ARC's intellectual property portfolio," said Chuck Winternitz, director of operations for ARC. "The polymers included broaden the company's pipeline and may be useful in the development of films, gels and instillates for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry